We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Hologic (HOLX) Q2: Wall Street Projections for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Hologic (HOLX - Free Report) will report quarterly earnings of $1.02 per share in its upcoming release, pointing to a year-over-year decline of 1%. It is anticipated that revenues will amount to $1 billion, exhibiting a decline of 1.6% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Hologic metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- Diagnostics- Cytology and Perinatal' should come in at $119.94 million. The estimate points to a change of -0.5% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Diagnostics- Molecular Diagnostics' should arrive at $328.58 million. The estimate indicates a change of +1.8% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Diagnostics- Blood Screening' will reach $4.99 million. The estimate indicates a year-over-year change of -27.6%.
It is projected by analysts that the 'Revenues- Breast Health- Breast Imaging' will reach $282.58 million. The estimate indicates a change of -7.9% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Skeletal Health' reaching $18.00 million. The estimate indicates a change of -33.6% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenue- Total Breast Health' of $369.50 million. The estimate suggests a change of -3.9% year over year.
Analysts expect 'Revenue- Total Diagnostics' to come in at $453.52 million. The estimate points to a change of +0.8% from the year-ago quarter.
Analysts predict that the 'Revenue- GYN Surgical' will reach $161.11 million. The estimate points to a change of +3.3% from the year-ago quarter.
The consensus estimate for 'Revenues- Breast Health- Interventional Breast Solutions' stands at $86.91 million. The estimate points to a change of +11.6% from the year-ago quarter.
Over the past month, Hologic shares have recorded returns of -5.4% versus the Zacks S&P 500 composite's -4.3% change. Based on its Zacks Rank #3 (Hold), HOLX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into Hologic (HOLX) Q2: Wall Street Projections for Key Metrics
Wall Street analysts forecast that Hologic (HOLX - Free Report) will report quarterly earnings of $1.02 per share in its upcoming release, pointing to a year-over-year decline of 1%. It is anticipated that revenues will amount to $1 billion, exhibiting a decline of 1.6% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Hologic metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Revenues- Diagnostics- Cytology and Perinatal' should come in at $119.94 million. The estimate points to a change of -0.5% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Diagnostics- Molecular Diagnostics' should arrive at $328.58 million. The estimate indicates a change of +1.8% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Diagnostics- Blood Screening' will reach $4.99 million. The estimate indicates a year-over-year change of -27.6%.
It is projected by analysts that the 'Revenues- Breast Health- Breast Imaging' will reach $282.58 million. The estimate indicates a change of -7.9% from the prior-year quarter.
Analysts' assessment points toward 'Revenue- Skeletal Health' reaching $18.00 million. The estimate indicates a change of -33.6% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenue- Total Breast Health' of $369.50 million. The estimate suggests a change of -3.9% year over year.
Analysts expect 'Revenue- Total Diagnostics' to come in at $453.52 million. The estimate points to a change of +0.8% from the year-ago quarter.
Analysts predict that the 'Revenue- GYN Surgical' will reach $161.11 million. The estimate points to a change of +3.3% from the year-ago quarter.
The consensus estimate for 'Revenues- Breast Health- Interventional Breast Solutions' stands at $86.91 million. The estimate points to a change of +11.6% from the year-ago quarter.
View all Key Company Metrics for Hologic here>>>
Over the past month, Hologic shares have recorded returns of -5.4% versus the Zacks S&P 500 composite's -4.3% change. Based on its Zacks Rank #3 (Hold), HOLX will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>